Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues
British Journal of Pharmacology · 2026-11 · 183 (22) · 6627-6648
DOI: 10.1111/bph.70604 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-07-16. Written by Bharath Srinivasan and 1 co-authors. Institution: School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK. Major MEDLINE topics: Drug Discovery, Amino Acids. Cited 2 times so far (Crossref); 128 references.
Abstract (original language)
Covalent inhibitors have re‐emerged as a powerful class of therapeutics due to their prolonged target engagement, ability to decouple pharmacokinetic availability from pharmacodynamic outcome, potential for high selectivity and ability to modulate traditionally ‘undruggable’ targets. Historically, cysteine residues have dominated covalent drug discovery owing to their unique nucleophilicity and relative scarcity in the proteome. However, the desire to broaden the chemical scope of covalent therapeutics has driven a surge of interest in irreversibly targeting other amino acid residues, such as lysine, serine, tyrosine, threonine and histidine. This review explores the outstanding questions and challenges in developing covalent inhibitors beyond cysteine, highlighting current warhead chemistries, strategies for achieving selectivity, proteomic mapping advances, assessment of the intrinsic reactivity of the electrophiles targeting non‐cysteine residues and opportunities for expanding the druggable proteome. We also discuss future directions and the pharmacological implications of non‐cysteine covalent modifications in therapeutic contexts. LINKED ARTICLES This article is part of a themed issue Re‐emergence of Covalent Modulation in Drug Discovery. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.22/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK.
- Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
- Cancer Research Horizons, Cancer Research UK, London, UK.
- Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Glasgow, UK.
Cite
APA
Srinivasan, B., & Taylor, J. B. (2026). Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues. British Journal of Pharmacology, 183(22), 6627-6648. https://doi.org/10.1111/bph.70604
Vancouver
Srinivasan B, Taylor JB. Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues. British Journal of Pharmacology. 2026;183(22):6627-6648. doi:10.1111/bph.70604
BibTeX
@article{Srinivasan2026,
author = {Srinivasan, Bharath and Taylor, John B},
title = {Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {22},
pages = {6627--6648},
doi = {10.1111/bph.70604}
}
EUVIMED